A team of biologists who banded together to support COVID-19 science determined the atomic structure of a coronavirus protein thought to help the pathogen evade and dampen response from human immune cells. The structural map – which is now published in the journal PNAS, but has been open-access for the scientific community since August – has laid the groundwork for new antiviral treatments and enabled further investigations into how the newly emerged virus ravages the human body.
A new approach for studying phages-bacteria interactions will help scientists study the intricate offensive and defensive chemical tactics used by parasite and host. These microscopic battles have implications for medicine development, agricultural research, and climate science.
Berkeley Lab bioscientists are part of a nationwide research project, called ENCODE, that has generated a detailed atlas of the molecular elements that regulate our genes. This enormous resource will help all human biology research moving forward.
Our biomanufacturing experts are helping accelerate the development of new COVID-19-fighting technologies. Learn how the scientists at the ABPDU are collaborating with biotech companies to scale up and optimize production of coronavirus-targeting antibodies and a highly accurate rapid testing system.
Biomanufacturing – harnessing biological processes in cells and microbes to design and manufacture products – is revolutionizing how we make everything from futuristic consumer goods to sustainable fuels to breakthrough medicines. Every biomanufactured product can be traced back to discoveries in the lab, but translating that science into a real-world product can be tricky. Berkeley Lab is helping to move great ideas, like outdoor gear made from algae oil, from conception to commercialization.
A new test agent can easily and efficiently detect the misfolded protein aggregates that cause devastating neurological diseases in blood samples. The technology could lead to early diagnosis of prion, Alzheimer’s, and Parkinson’s diseases for the first time.
The unique ways in which proteins fold dictate their interplay with diseases and medicines, so understanding their twists and turns is key to designing effective drugs. While new drug design is serious work, discovering how proteins fold can be fun, too: A crowdsourcing game called Foldit allows players to try different fold configurations for points
This video and accompanying article highlight the decades of discoveries, achievements and progress in particle accelerator R&D at Berkeley Lab. These accelerators have enabled new explorations of the atomic nucleus; the production and discovery of new elements and isotopes, and of subatomic particles and their properties; created new types of medical imaging and treatments; and provided new insight into the nature of matter and energy, and new methods to advance industry and security, among other wide-ranging applications.
Nearly ten years ago, a group of Israeli clinical researchers emailed Berkeley Lab geneticist Len Pennacchio to ask for his team’s help in solving the mystery of a rare inherited disease that caused extreme, and sometimes fatal, chronic diarrhea in children. Now, following an arduous investigative odyssey that expanded our understanding of regulatory sequences in the human genome, the multinational scientific group has announced the discovery of the genetic explanation for this disease.
Scientists have invented a new “synthetic antibody” that could make screening for diseases easier and less expensive than current go-to methods. Writing in the journal Nano Letters, a team led by Markita Landry of Berkeley Lab and UC Berkeley describes how peptoids – synthetically produced molecules, first created by Ron Zuckermann at Berkeley Lab’s Molecular Foundry, that